Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2017-05-29 Interim / Quarterly Rep…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Half-year financial report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR FINANCIAL REPORT 1st HALF 2016' and explicitly includes 'Activity Report', 'Financial Statements at 30 June 2016', and 'Note to the Financial Statements'. It provides a comprehensive review of business activity, legal transactions, and financial developments for the first half of the fiscal year. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H2 2016
2017-05-29 English
Quantum Genomics organise une journée leaders d'opinion à New York sur les résultats de son étude de phase IIa dans l'hypertension et son prochain essai clinique aux Etats-Unis
Investor Presentation Classification · 95% confidence The document is a press release announcing a future event: a Key Opinion Leader (KOL) & Investor Day scheduled for June 27, 2017, in New York. The purpose of this event is to present results from a Phase IIa study and discuss the next clinical trial. This announcement is not the report itself (like 10-K or IR), nor is it a standard earnings release (ER) or a formal regulatory filing like a DVA or DIV. It is an announcement specifically targeting investors and key opinion leaders about upcoming data presentation and strategy. This fits best under the category of Investor Presentation (IP) materials being announced, or more generally, a communication aimed at investors about future strategic/data events. Since the document is an announcement *about* an event where presentations will occur, and it details the speakers and agenda, it strongly aligns with the intent behind an Investor Presentation (IP) or a related investor communication. However, given the options, the event itself is a presentation for investors. If the document were the actual presentation slides, it would be IP. As a press release announcing the event, it is a form of investor relations communication. Since there isn't a specific code for 'Event Announcement,' and the content focuses heavily on presenting data and strategy to investors, it is closely related to Investor Presentation (IP). Alternatively, because it is a press release announcing future activity, it could be considered a general Regulatory Filing (RNS) if it doesn't fit elsewhere. Given the high specificity of the event (KOL & Investor Day focused on clinical data), it is a targeted investor communication. I will classify it as Investor Presentation (IP) as it is announcing the delivery of investor-focused material, even though it is the announcement itself, which sometimes falls under RPA/RNS. However, the core subject matter is the presentation content. Given the short length and announcement nature, RPA might be considered, but the content is too specific. I will lean towards IP as the subject matter is the presentation itself.
2017-05-23 French
Lancement du ' QG des Actionnaires ', le club des actionnaires de Quantum Genomics
Regulatory Filings Classification · 95% confidence The document is a press release ("Communiqué de presse") announcing the creation of a shareholder club called "Le QG des Actionnaires" (The Shareholders' HQ). This club is designed to foster better communication and provide exclusive information (press releases, annual reports, shareholder letters, AGM documentation) to existing shareholders. While it mentions future receipt of documents like annual reports and AGM documentation, the primary purpose of this specific text is the announcement of a new shareholder engagement initiative, not the release of the financial report itself. This type of announcement, which details engagement strategy and communication channels, does not fit neatly into the specific financial filing categories (10-K, ER, IR, etc.). It is a general corporate communication regarding investor relations and shareholder engagement. Given the options, it is closest to a general corporate announcement, but since it is not a standard regulatory filing (RNS) or a specific report, and it deals with shareholder interaction, it is best classified as a general corporate communication. However, looking closely at the definitions, none perfectly capture a 'Shareholder Club Launch Announcement'. It is not a Director's Dealing (DIRS), Dividend Notice (DIV), or Proxy Solicitation (PSI). Since it is a formal announcement about corporate structure/engagement aimed at investors, and it is not a core financial report, the most appropriate fallback category for a non-standard, non-financial-result-focused corporate announcement is 'Regulatory Filings' (RNS) as a general catch-all for non-standard corporate news, or potentially 'Board/Management Information' (MANG) if viewed as management communicating strategy, but RNS is safer for general press releases not covered elsewhere. Given the context of investor relations and communication structure, RNS is the most suitable fallback for this type of non-standard corporate news release.
2017-05-19 French
Quantum Genomics organisera une téléconférence le 19 juin 2017 pour commenter les résultats de son étude de phase IIa dans l'hypertension artérielle
Regulatory Filings Classification · 95% confidence The document is a press release dated May 9, 2017, announcing that Quantum Genomics will hold a conference call on June 19, 2017, to comment on the results of its Phase IIa study in arterial hypertension, which will be presented at the European Society of Hypertension (ESH) Congress on June 18. The core purpose of this document is to inform the financial community about an upcoming event (the conference call) where management will discuss results, and it explicitly states that the access details for this call will be communicated later via a press release. This structure—announcing an upcoming event where results will be discussed, rather than containing the full results or the transcript itself—strongly suggests it is an announcement about a future communication event. Since it is announcing a conference call (a form of earnings/results discussion), and it is a short press release format, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the call was about earnings, but here it is about study results. Given the options, and that it is an announcement about a future event/call, it is closest to an announcement related to investor communication. However, since it is not the transcript (CT) and not the full earnings release (ER), and it is a general announcement, RNS is a strong candidate. If we interpret the announcement of the conference call as the primary action, it is an announcement. Since the document is short and serves to inform about future events/communications, RNS is the most appropriate fallback for a specific announcement not covered by other codes like DIV or ER.
2017-05-09 French
Nomination de Bruno Besse au poste de Directeur médical
Board/Management Information Classification · 99% confidence The document is a press release ('Communiqué de presse') dated April 25, 2017, announcing the appointment of Dr. Bruno Besse as the Chief Medical Officer ('Directeur médical'). This announcement concerns a change in senior management personnel. According to the definitions, the category for 'Announcement of changes in the company's board of directors or senior management' is Board/Management Information (MANG). The document length is short (3279 chars), but its content is a direct announcement of a management change, not an announcement about the publication of a separate report, making MANG the most appropriate classification.
2017-04-25 French
Éligibilité des titres Quantum Genomics au PEA-PME
Regulatory Filings Classification · 95% confidence The document is a press release ("Communiqué de presse") from Quantum Genomics dated April 11, 2017. The core subject is confirming that the company's shares are eligible for inclusion in the PEA-PME (a specific French retail investment scheme). This announcement relates to the company's structure, compliance with regulatory criteria (employee count, revenue/balance sheet limits), and the resulting implications for investors. This type of announcement, which details compliance status or specific corporate structure facts that don't fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, CAP), is best classified as a general Regulatory Filing or announcement. Given the options, 'Regulatory Filings' (RNS) serves as the most appropriate fallback for miscellaneous regulatory compliance confirmations that are not standard SEC/exchange filings or specific corporate actions like dividends or share issues. It is not an AGM material, an earnings release, a management change, or a financing update, but rather a compliance status update.
2017-04-11 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.